Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Gender and the hygiene hypothesis.
T(H)17 cytokines in autoimmune neuro-inflammation.
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis.
HLA-DRB1*15:01 and multiple sclerosis: a female association?
Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS
Sex ratio of multiple sclerosis and clinical phenotype.
Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
US patent office grants patent claiming dosing regimen for TECFIDERA™ (dimethyl fumarate)
Best practice in the use of natalizumab in multiple sclerosis.
Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
Testosterone treatment in multiple sclerosis: a pilot study.
[Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)].
The natural history of primary progressive MS in British Columbia, Canada.
MHC transmission: insights into gender bias in MS susceptibility.
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-Related Hospitalizations: Integrated Analysis of the Delayed-Release Dimethyl Fumarate Phase III Studies.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis.
Demyelination of the hippocampus is prominent in the cuprizone model.
Multiple sclerosis in Hispanics: a study of clinical disease expression.

Pages